The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Reaction from the life sciences industry to the Autumn Budget was mixed, with the government opting for a more macro focus on business scaling.

Enthorin has signed an option-to-license deal with Rumi to advance ENT-7340 for FXS, as well as other intellectual and developmental disabilities.

Formation Bio has launched the Formation Bio Drug Development Accelerator Fund to broaden the company's clinical-stage medicines portfolio.

Gameto’s lead asset is a cell-based IVM tool, Fertilo, which is currently in late-stage development within the US.

Astellas will continue development of DAX-044, which is expected to enter Phase I in 2027. Credit: Lightspring / Shutterstock.com. Astellas Pharma has inked a billion-dollar licensing deal with ...

Anthropic hopes Powerful AI will “match or exceed the cognitive capabilities of top human experts across scientific disciplines”.

The FDA has granted orphan drug designation to Octant’s OCT-980, an investigational oral small molecule, to treat retinitis pigmentosa.

Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies.

Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes ...

Pathos AI has secured $237m in a Series E round to expand its clinical oncology pipeline and scale its AI drug development platform.

British biotech generally raised more across public and private markets in Q3 2026, despite an overall downturn in the flow of VC more generally into the UK.